erikgunnarsson 🇺🇸 🇪🇺
@gunnarssonerik1
disclaimer:🚨 tweets are my own opinions & should not be seen as investment advice Corporate-finance & stocks (sp) are associated with risks & uncertainties📌
Unlocked 🔐 🪙📌
AbCellera Biologics next targets 👀 $abcl T-cell engager molecules 🚨🚀
The shorts keep increasing, and it's shown in the candles. Some shorts are - 100% and should be liquidated anytime A new trading range is carved out in the price $abcl AbCellera @AbCelleraBio
Day 35 of researching a stock a day until I can quit my job. Today we’re looking at AbCellera Biologics $ABCL
Make this make sense: $GOOGL cloud growth: 32% $PLTR revenue growth: 39% $GOOGL cloud margin: 21% $PLTR margin: 13% $GOOGL PE: 20x $PLTR PE: 250x
The us trade war is over
*US AND EU CLOSE IN ON 15% TARIFF DEAL: FT
AbCellera Biologics $abcl
We need to have eyes on new drugs and devices as soon as they hit the market. And with big data, we should never miss a big safety issue — much less wait 20 years to see it.
This might be of interest for those who want to understand the space of AbCellera’s potential first and best in class monoclonal antibody ABCL635 for hot flashes that will start phase I very soon $ABCL
Hormone Replacement Therapy (HRT) has long been an important treatment option for women to alleviate symptoms of menopause, among other potential health benefits. Over the last two decades, however, HRT has been surrounded by confusing narratives about potential risks. We're…
$ABCL - BREAKING NEWS KeyBanc raises price target by 100% (!), from $5 to $10 gurufocus.com/news/2974638/a…
AbCellera Biologics TCEs 👀
Big deal - $700M upfront. $ABBV The real takeaway? TCEs are evolving in real time. We’re now seeing trispecifics with validated dual-antigen logic clearing a $700M upfront bar, despite observable but not yet durable activity. (eg., based on ORR) Dual-antigen targeting on both…
Reversal bullish ✅️🫂 AbCellera Biologics @AbCelleraBio $abcl
Consolidating ✅️🫂